Skip to content

Exploratory Study of Effective Core Formula of Chinese Medicine to Treat Primary Insomnia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01613183
Enrollment
2
Registered
2012-06-07
Start date
2012-05-31
Completion date
Unknown
Last updated
2012-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Insomnia

Brief summary

The objective of this study is to screen the effective core formulation in insomnia treatment with Chinese medicine with a double-blind, randomized, placebo-controlled trial.

Interventions

The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.

OTHERthe dummy of a Chinese Medicine prescription

Patients in placebo group will receive the dummy of the core drug patterns screened in previous retrospective study. The previous core drug patterns include Fried semen Ziziphi Spinosae, Tuckahoe, Preparation of Polygala, Chinese Angelica root, Lotus heart, White peony root, dried tangerine peel, acorus calamus, Coptis chinensis, and Licorice health.

Sponsors

China Academy of Chinese Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* aged between 18 and 65 years, * meeting the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) of insomnia, * Spiegel scale score is ≥ 18, * The informed consent must be obtained from patient

Exclusion criteria

* total sleep time ≤ 2 hours, * secondary insomnia, * Self-rating Anxiety Scale (SAS) score ≥ 18, * Beck Depression Inventory (BDI) score ≥ 6, * having hypertension, diabetes, stroke, and coronary heart disease, * have drug abuse history, * pregnancy or preparing to pregnancy, * used immunotherapy or hormone therapy in past 1 years, * participating in another clinical trial.

Design outcomes

Primary

MeasureTime frame
change from baseline in Total Sleep Time (TST) at 4 weeksbaseline and 4 weeks

Secondary

MeasureTime frame
change from baseline in sleep onset latency at 4 weeksbaseline and 4 weeks
change from baseline in wake time after sleep onset at 4 weeksbaseline and 4 weeks
change from baseline in sleep efficiency at 4 weeksbaseline and 4 weeks
change from baseline in Pittsburgh sleep quality index (PSQI) at 4 weeksbaseline and 4 weeks
change from baseline in Chinese Medicine symptoms and signs at 4 weeksbaseline and 4 weeks

Countries

China

Contacts

Primary ContactPeng Li, Bachelor
leepanns@gmail.com+8613810991638

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026